{
  "docId": "019de514-f120-743f-9d00-70915b7d1fa5",
  "docSlug": "a9055659e75fd1b92a3c529616eb6953",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 49 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 49,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "kpi_overview",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 22,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de514-f120-743f-9d00-70915b7d1fa5/11",
  "deckHref": "/decks/019de514-f120-743f-9d00-70915b7d1fa5",
  "deckJsonHref": "/decks/019de514-f120-743f-9d00-70915b7d1fa5.json",
  "deckAnchorHref": "/decks/019de514-f120-743f-9d00-70915b7d1fa5#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.31,
        "w": 0.26,
        "x": 0.058,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Total Company Revenue\nMillions USD\n3,765\n184 FX Impact3\n3,581\nFY21\n3,768\nFY22",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e39dc5d-3daa-447d-a2e1-6545f9a703be",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.37,
        "w": 0.208,
        "x": 0.342,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Vision Care\n$2,373M\n63%\n37%\nConsumer\nContact Lens",
      "attrs": null,
      "subkind": "donut",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b5ac4c2-dcd7-4e34-bb84-a02f7de20fc0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.37,
        "w": 0.19,
        "x": 0.56,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Surgical\n$718M\n53%\n27%\n20%\nImplantables\nEquipment\nConsumables/Other",
      "attrs": null,
      "subkind": "donut",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84b8f956-cc34-46d7-a762-10227cafbe8a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.37,
        "w": 0.19,
        "x": 0.77,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Ophthalmic\nPharmaceuticals\n$677M\n60%\n40%\nU.S.\nInternational",
      "attrs": null,
      "subkind": "donut",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c97ca7b-2926-4b95-b33e-2fdf7e3bb957",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.26,
        "w": 0.19,
        "x": 0.57,
        "y": 0.65
      },
      "kind": "list",
      "text": "+8%\nGrowth in implantables (+4% reported revenue\ngrowth; +12% organic revenue growth 1.2)\nStrong demand for consumables (2% reported\nrevenue growth; 9% organic revenue growth 1.2)\nLuxSmart™™ launched in 19 countries in Europe\nand ~10 additional countries expected in 2023\nExpansion of the portfolio with AcuFocus\nacquisition, using cash on hand, in early 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31fd9ea8-2216-4c08-9882-b9fc471e5466",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.26,
        "w": 0.19,
        "x": 0.35,
        "y": 0.65
      },
      "kind": "list",
      "text": "+6%\nStrong demand for key franchises:\nLumify® (+21% reported revenue growth)\nOcuvite® + PreserVision® (+10% reported\nrevenue growth)\nDaily SiHy (+46% reported revenue growth)\nBausch + Lomb ULTRA® (+4% reported revenue\ngrowth)\nBioTrue ONEday® (+4% reported revenue growth)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "613612b5-59da-477d-8cb4-4e92ce36d54b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.22,
        "x": 0.09,
        "y": 0.56
      },
      "kind": "list",
      "text": "+5%\norganic revenue1,2 growth\nSecond consecutive full year of organic\nrevenue growth 1,2\nChina continued to impact top line\n(~150bps) during FY22 as country's\nCOVID conditions and policies evolved\nFX conditions during FY22 impacted\nbusiness by $184M",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a87ec47f-e556-434c-bde5-f3e8352cda4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.26,
        "w": 0.19,
        "x": 0.78,
        "y": 0.65
      },
      "kind": "list",
      "text": "+0%\nStrong performance in international portfolio (2%\nreported revenue decline; 7% organic revenue\ngrowth 1.2)\nVyzulta®: 31% reported revenue growth vs. FY21;\ngeo-expansion continuing in 2023\nPositive early stages of XIPERE® U.S. launch\nNOV03 PDUFA date June 28, 2023; expect\nCanada filing in 1Q23",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ac1502ae-6d97-4d0a-ae99-313bd5dee03e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.66,
        "x": 0.16,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "1. This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.\n2. Organic revenue growth/change, a non-GAAP ratio, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations.\n3. FX impact is determined by comparing 2022 reported amounts adjusted to exclude currency impact, calculated using 2021 monthly average exchange rates, to the actual 2021 reported amounts.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "17b02baa-dbb2-418e-b133-ba6e30792a3b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.64,
        "x": 0.045,
        "y": 0.08
      },
      "kind": "title",
      "text": "FY22 Financial Highlights & Segment Drivers",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2e057940-f57e-4d36-88cb-6590058d1630",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 10,
      "beatId": "7dc62337-b2ed-4c41-8d32-808d2f972bf7",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The presentation showcases the company's strong financial performance and strategic advancements, providing satisfaction to investors",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 10,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "d15671c2-99b6-48fa-89dc-6302733eef20",
      "evidence": "The presentation highlights the company's financial performance and strategic advancements, implying the consequences of not investing in Bausch + Lomb",
      "position": 0,
      "objective": "Emphasize the importance of Bausch + Lomb's solutions by highlighting the cost of inaction",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}